UB Paderborn / Katalog / Suche / in CDI

1099 Epidemiology and Diagnostic Evaluation of Patients With Liver Abscesses at an Academic Hospital in Washington, DC

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S621-S621

2019

Link zum Volltext

Verfügbarkeit prüfen

1241 Are You Full? An Analysis of Online Patient Resources for Gastroparesis

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S692-S692

2019

Link zum Volltext

Verfügbarkeit prüfen

14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2)

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB16-AB16

2020

Link zum Volltext

Verfügbarkeit prüfen

257 White Women Are More Frequently Assessed for Hereditary Colon Cancer Risks Compared to Minority Women

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S148-S148

2019

Link zum Volltext

Verfügbarkeit prüfen

25800 Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB70-AB70

2021

Link zum Volltext

Verfügbarkeit prüfen

267 Family Comes First: GI Providers May Inconsistently Perform Multi-Generational Family History When Assessing Colon Cancer Risk

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S154-S154

2019

Link zum Volltext

Verfügbarkeit prüfen

27368 Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE VIVID bimekizumab in moderate to severe plaque psoriasis phase 3 trial

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB137-AB137

2021

Link zum Volltext

Verfügbarkeit prüfen

A 40-Amino Acid Segment of the Growth Hormone Receptor Cytoplasmic Domain Is Essential for GH-induced Tyrosine-phosphorylated Cytosolic Proteins (∗)

The Journal of biological chemistry, 1995-03, Vol.270 (11), p.6261-6266

1995

Link zum Volltext

Verfügbarkeit prüfen

430: The use of a vaginal birth after cesarean delivery prediction tool in patients scheduled for repeat cesarean delivery

American journal of obstetrics and gynecology, 2016, Vol.214 (1), p.S236-S237

2016

Link zum Volltext

Verfügbarkeit prüfen

438 IDENTIFYING PATIENTS WHO ARE NO LONGER CIRRHOTIC AFTER THERAPY FOR CHRONIC HEPATITIS C

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-778-S-778

2021

Link zum Volltext

Verfügbarkeit prüfen

5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) for previously untreated metastatic pancreatic adenocarcinoma

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.TPS517-TPS517

2017

Link zum Volltext

Verfügbarkeit prüfen

747: A comparison of obstetrical outcomes and costs between misoprostol and dinoprostone

American journal of obstetrics and gynecology, 2015, Vol.212 (1), p.S364-S364

2015

Link zum Volltext

Verfügbarkeit prüfen

953-36 L-Arginine Administration Improves Left Ventricular Performance in Neonatal Lambs Following Cardiopulmonary Bypass and Two Hours of Global Hypothermic Ischemia

Journal of the American College of Cardiology, 1995-02, Vol.25 (2), p.201A-201A

1995

Link zum Volltext

Verfügbarkeit prüfen

The African Descent and Glaucoma Evaluation Study (ADAGES) III

Ophthalmology (Rochester, Minn.), 2019-01, Vol.126 (1), p.156-170

2019

Link zum Volltext

Verfügbarkeit prüfen

The African Descent and Glaucoma Evaluation Study (ADAGES) III: Contribution of Genotype to Glaucoma Phenotype in African Americans: Study Design and Baseline Data

Ophthalmology (Rochester, Minn.), 2019-01, Vol.126 (1), p.156-170

2019

Link zum Volltext

Verfügbarkeit prüfen

Application of biotechnology and transgenic animals toward the study of growth hormone

The American journal of clinical nutrition, 1993-08, Vol.58 (2), p.296S-298S

1993

Link zum Volltext

Verfügbarkeit prüfen

Assessment of differential gene expression in vestibular epithelial cell types using microarray analysis

Brain research. Molecular brain research., 2005-01, Vol.133 (1), p.19-36

2005

Link zum Volltext

Verfügbarkeit prüfen

Asset Securitization Report, "Yes, The President's Words Do Matter, Even For Student Loan Litigation"

Mondaq business briefing, 2017-08-07

Cioffi, Joseph

2017

Link zum Volltext

Verfügbarkeit prüfen

Bankruptcy Relief For Cannabis-Adjacent Debtors? It Gets Hazy

Mondaq business briefing, 2024-02-20

Cioffi, Joseph

2024

Link zum Volltext

Verfügbarkeit prüfen

A Bariatric Curveball: A Rare Case of Recurrent Lactobezoars after Roux-en-Y Gastric Bypass Surgery

Military medicine, 2020-08, Vol.185 (7-8), p.e1294-e1297

2020

Link zum Volltext

Verfügbarkeit prüfen

Behind-The-Scenes Strategies For Success: We Speak To Revenue Connections On Improving Collections To Combat Latent Market Risks

Mondaq business briefing, 2019-04-30

Cioffi, Joseph

2019

Link zum Volltext

Verfügbarkeit prüfen

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study

Journal of the American Academy of Dermatology, 2020-11, Vol.83 (5), p.1367-1374

2020

Link zum Volltext

Verfügbarkeit prüfen

Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study

Skin (Milwood, N.Y.), 2019-11, Vol.3, p.S35

2019

Link zum Volltext

Verfügbarkeit prüfen

Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study

Skin (Milwood, N.Y.), 2019-11, Vol.3, p.S34

2019

Link zum Volltext

Verfügbarkeit prüfen

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

The Lancet (British edition), 2021-02, Vol.397 (10273), p.487-498

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

1099 Epidemiology and Diagnostic Evaluation of Patients With Liver Abscesses at an Academic Hospital in Washington, DC

1241 Are You Full? An Analysis of Online Patient Resources for Gastroparesis

14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2)

257 White Women Are More Frequently Assessed for Hereditary Colon Cancer Risks Compared to Minority Women

25800 Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial

267 Family Comes First: GI Providers May Inconsistently Perform Multi-Generational Family History When Assessing Colon Cancer Risk

27368 Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE VIVID bimekizumab in moderate to severe plaque psoriasis phase 3 trial

A 40-Amino Acid Segment of the Growth Hormone Receptor Cytoplasmic Domain Is Essential for GH-induced Tyrosine-phosphorylated Cytosolic Proteins (∗)

430: The use of a vaginal birth after cesarean delivery prediction tool in patients scheduled for repeat cesarean delivery

438 IDENTIFYING PATIENTS WHO ARE NO LONGER CIRRHOTIC AFTER THERAPY FOR CHRONIC HEPATITIS C

5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) for previously untreated metastatic pancreatic adenocarcinoma

747: A comparison of obstetrical outcomes and costs between misoprostol and dinoprostone

953-36 L-Arginine Administration Improves Left Ventricular Performance in Neonatal Lambs Following Cardiopulmonary Bypass and Two Hours of Global Hypothermic Ischemia

The African Descent and Glaucoma Evaluation Study (ADAGES) III

The African Descent and Glaucoma Evaluation Study (ADAGES) III: Contribution of Genotype to Glaucoma Phenotype in African Americans: Study Design and Baseline Data

Application of biotechnology and transgenic animals toward the study of growth hormone

Assessment of differential gene expression in vestibular epithelial cell types using microarray analysis

Asset Securitization Report, "Yes, The President's Words Do Matter, Even For Student Loan Litigation"

Bankruptcy Relief For Cannabis-Adjacent Debtors? It Gets Hazy

A Bariatric Curveball: A Rare Case of Recurrent Lactobezoars after Roux-en-Y Gastric Bypass Surgery

Behind-The-Scenes Strategies For Success: We Speak To Revenue Connections On Improving Collections To Combat Latent Market Risks

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study

Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study

Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Suchergebnisse filtern